RhumbLine Advisers’s Fennec Pharmaceuticals FENC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $281K | Buy |
33,897
+533
| +2% | +$4.42K | ﹤0.01% | 3027 |
|
|
2025
Q1 | $203K | Sell |
33,364
-935
| -3% | -$5.69K | ﹤0.01% | 3096 |
|
|
2024
Q4 | $217K | Buy |
34,299
+3,911
| +13% | +$24.7K | ﹤0.01% | 3150 |
|
|
2024
Q3 | $152K | Buy |
30,388
+1,278
| +4% | +$6.39K | ﹤0.01% | 3361 |
|
|
2024
Q2 | $178K | Buy |
29,110
+8,987
| +45% | +$54.9K | ﹤0.01% | 3290 |
|
|
2024
Q1 | $224K | Buy |
20,123
+240
| +1% | +$2.67K | ﹤0.01% | 3114 |
|
|
2023
Q4 | $223K | Sell |
19,883
-664
| -3% | -$7.45K | ﹤0.01% | 3127 |
|
|
2023
Q3 | $154K | Buy |
20,547
+816
| +4% | +$6.13K | ﹤0.01% | 3291 |
|
|
2023
Q2 | $174K | Buy |
+19,731
| New | +$174K | ﹤0.01% | 3308 |
|
|
2021
Q2 | – | Sell |
-19,802
| Closed | -$123K | – | 3030 |
|
|
2021
Q1 | $123K | Sell |
19,802
-220
| -1% | -$1.37K | ﹤0.01% | 2912 |
|
|
2020
Q4 | $149K | Buy |
20,022
+1,600
| +9% | +$11.9K | ﹤0.01% | 2903 |
|
|
2020
Q3 | $112K | Sell |
18,422
-506
| -3% | -$3.08K | ﹤0.01% | 2845 |
|
|
2020
Q2 | $158K | Buy |
+18,928
| New | +$158K | ﹤0.01% | 2850 |
|
|
2019
Q2 | – | Sell |
-13,375
| Closed | -$65K | – | 2981 |
|
|
2019
Q1 | $65K | Sell |
13,375
-280
| -2% | -$1.36K | ﹤0.01% | 2903 |
|
|
2018
Q4 | $87K | Buy |
+13,655
| New | +$87K | ﹤0.01% | 2899 |
|